Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TsumuraTSMRF 79 Debt-to-EBITDA is 2.83 as of Mar. 2026, which is 35% above its 10-year median of 2.09. GuruFocus rates TSMRF with a GF Score™ of 79/100 and a GF Value™ of $25.74. The stock has 4 warning signs investors should review. Among 691 Drug Manufacturers companies, Tsumura ranks worse than 61.65% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Tsumura's Debt-to-EBITDA or its related term are showing as below:
TSMRF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.23 Med: 2.09 Max: 2.53
Current: 2.45
During the past 13 years, the highest Debt-to-EBITDA Ratio of Tsumura was 2.53. The lowest was 1.23. And the median was 2.09.
TSMRF's Debt-to-EBITDA is ranked worse than 61.65% of 691
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs TSMRF: 2.45
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Tsumura Debt-to-EBITDA Related Terms
Tsumura Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Tsumura's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tsumura's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tsumura Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tsumura's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Tsumura's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Tsumura (TSMRF) has a Debt-to-EBITDA of 2.83 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Tsumura. This is 35% above median its historical median of 2.09. Over the past decade, Tsumura's Debt-to-EBITDA has ranged from 1.23 to 2.53. According to the industry distribution chart, Tsumura ranks #426 out of 691 companies in the Drug Manufacturers industry, placing it in the top 61.6%.
Is Tsumura's Debt-to-EBITDA too high?
Tsumura's current Debt-to-EBITDA of 2.83 is 35% above median its 10-year median of 2.09. Over the past 10 years, this metric has ranged from a low of 1.23 to a high of 2.53. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Tsumura's value of 2.83 is 68.5% above this industry median. Based on the distribution chart, Tsumura ranks #426 out of 691 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Tsumura has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Tsumura's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tsumura ranks #426 out of 691 companies for Debt-to-EBITDA. This places Tsumura in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. Tsumura's value of 2.83 is 68.5% above this benchmark. Historically, Tsumura's own Debt-to-EBITDA has ranged from 1.23 to 2.53 over the past decade. While the company's 10-year median is 2.09 vs. the industry median of 1.68, Tsumura has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tsumura's current Debt-to-EBITDA of 2.83 is 68.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Tsumura. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tsumura's current Debt-to-EBITDA is 2.83, which is 35% above median its own 10-year median of 2.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tsumura stock overvalued right now?
Tsumura (TSMRF) has a current Debt-to-EBITDA of 2.83. The stock's GF Value™ is $25.74, compared to a current price of $23.20 — trading 9.9% below its estimated fair value. The current Debt-to-EBITDA is 2.83, which is 35% above median its 10-year median of 2.09 and 68.5% above the Drug Manufacturers industry median of 1.68. Tsumura's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Tsumura (TSMRF), the current Debt-to-EBITDA is 2.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tsumura (TSMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Tsumura stock appears to be undervalued.
The current stock price of $23.20 is trading 9.9% below its estimated GF Value™ of $25.74.
Key valuation signals for TSMRF:
Debt-to-EBITDA: 2.83 (35% above median its 10-year median of 2.09)
GF Value™: $25.74 vs. price of $23.20 (9.9% below fair value)
Industry Position: 68.5% above the Drug Manufacturers median (#426 of 691)
No single metric tells the full story. See the TSMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tsumura & Co is a specialty and generic drug manufacturing company. The company generates the majority of its revenue through prescription Kampo products, followed by over-the-counter medicines. It promotes its products through educational support at medical schools and by hosting seminars for physicians and consumers. The company specializes in developing, producing, and marketing Kampo formulations that integrate traditional herbal knowledge with modern pharmaceutical science to address various health conditions.
79GF Score
Get the complete analysis for TSMRF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSMRF has been successfully added to your 
